Pfizer Announces Failure of Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery

Pfizer announced today that the independent Data Monitoring Committee for the Phase 3 ATLAS trial evaluating Inlyta The study failing to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS) for patients treated with INLYTA compared with patients treated with placebo.